The sensitivity of CA19-9 and CEA for localized pancreatic cancer cases (stage 0-IIA, n = 9) were both 33.3%, while the sensitivity of serum and urine MIR1246 were 100% and 88.9%, respectively (data not shown). The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.